Efficacy and safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss.

Trial Profile

Efficacy and safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Brimapitide (Primary)
  • Indications Sensorineural hearing loss
  • Focus Registrational; Therapeutic Use
  • Acronyms HEALOS
  • Sponsors Auris Medical
  • Most Recent Events

    • 28 Nov 2017 Top-line results presented in an Auris Medical media release.
    • 28 Nov 2017 Primary endpoint (Pure tone average (PTA; average of the hearing threshold of three contiguous most affected hearing frequencies in dB)) has not been met according to an Auris Medical media release.
    • 13 Oct 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top